UNSPSC 51183512: Metformin orotate

This classification denotes an anti-diabetic agent with the molecular formula C5H4N2O4.C4H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KE1D8AP3J5, chemically known as 4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, compd. with n,n-dimethylimidodicarbonimidic diamide (1:1), but more generally known as metformin orotate, which bears US NIH Compound Identifier 124097.

European Medicines Agency schedules metformin orotate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08831MIG. Most nations, for tariff purposes, schedule metformin orotate under HS 29252900. SMILES: CN(C)C(=N)NC(=N)N.C1C([NH]C(=O)[NH]C1=O)C(=O)O.

UNSPSC 51183512 Metformin orotate, a Commodity code, encompasses specific generic pharmaceutical products that state and local health systems procure through cooperative purchasing vehicles and multi-source pharmaceutical contracts. The work involves supplying branded or generic formulations of metformin orotate — a diabetes medication — to state facilities, local health departments, correctional systems, and other public healthcare entities. State and local governments buy this code primarily through cooperative purchasing alliances that consolidate demand across multiple jurisdictions and negotiated master supply agreements with pharmaceutical manufacturers and authorized wholesalers, rather than through individual agency RFPs.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (Solicitation Number S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with response due March 26, 2026. MMCAP's solicitation encompasses metformin orotate alongside a broader portfolio of generic drugs and covers participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and comply with cGMP and Drug Supply Chain Security Act certification, maintain contractual relationships with at least two of the three wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence. The contract term runs two years for new respondents with optional extensions, and pricing evaluation weights price competitiveness at 75 percent, with all awarded products required to be available in the marketplace by May 15, 2026 and resulting agreements effective July 1, 2026. No specific dollar value or set-aside designations are disclosed in the available solicitation materials.